Latest Articles

Publication Date
All News Scientific
Merck Says Blockbuster Keytruda Outperforms Chemotherapy in Advanced Endometrial Cancer - Benzinga

Merck Says Blockbuster Keytruda Outperforms Chemotherapy in Advanced Endometrial Cancer Benzinga

Published: July 15, 2026, 5:25 p.m.
Read Full Article
GSK Advances New Maintenance Therapy Trial in Endometrial Cancer, Adding Depth to Its Oncology Pipeline - TipRanks

GSK Advances New Maintenance Therapy Trial in Endometrial Cancer, Adding Depth to Its Oncology Pipeline TipRanks

Published: July 15, 2026, 4:46 p.m.
Read Full Article
Pembrolizumab Monotherapy Improves PFS vs Chemotherapy in Frontline dMMR Endometrial Cancer - OncLive

Pembrolizumab Monotherapy Improves PFS vs Chemotherapy in Frontline dMMR Endometrial Cancer OncLive

Published: July 15, 2026, 3:58 p.m.
Read Full Article
KEYTRUDA® (pembrolizumab) as Monotherapy Significantly Improved Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer With Mismatch Repair Deficient (dMMR) Tumors Compared to Chemotherapy - BioSpace

KEYTRUDA® (pembrolizumab) as Monotherapy Significantly Improved Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer With Mismatch Repair Deficient (dMMR) Tumors Compared to Chemotherapy BioSpace

Published: July 15, 2026, 3:11 p.m.
Read Full Article
KEYTRUDA® (pembrolizumab) as Monotherapy Significantly Improved Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer With Mismatch Repair Deficient (dMMR) Tumors Compared to Chemotherapy - Business Wire

KEYTRUDA® (pembrolizumab) as Monotherapy Significantly Improved Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer With Mismatch Repair Deficient (dMMR) Tumors Compared to Chemotherapy Business Wire

Published: July 15, 2026, 10:45 a.m.
Read Full Article
Medroxyprogesterone Acetate Market Forecast 2026-2035: Growth Driven by Contraceptive Access and Hormone Therapy - News and Statistics - IndexBox

Medroxyprogesterone Acetate Market Forecast 2026-2035: Growth Driven by Contraceptive Access and Hormone Therapy - News and Statistics IndexBox

Published: July 10, 2026, 11:11 a.m.
Read Full Article
Cartherics emerges as Asia Pacific leader in off-the-shelf immune cell therapy - BiotechDispatch

Cartherics emerges as Asia Pacific leader in off-the-shelf immune cell therapy BiotechDispatch

Published: July 2, 2026, 12:04 a.m.
Read Full Article
Cartherics emerges as Asia Pacific leader in off the shelf immune cell therapy - PharmaDispatch

Cartherics emerges as Asia Pacific leader in off the shelf immune cell therapy PharmaDispatch

Published: July 1, 2026, 1:09 a.m.
Read Full Article
Surgery or Hormonal Therapy for Rectovaginal Endometriosis? - Medscape

Surgery or Hormonal Therapy for Rectovaginal Endometriosis? Medscape

Published: June 30, 2026, noon
Read Full Article
Does Surgery Outperform Hormonal Therapy for Rectovaginal Endometriosis? - Medscape

Does Surgery Outperform Hormonal Therapy for Rectovaginal Endometriosis? Medscape

Published: June 30, 2026, noon
Read Full Article
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!